Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.

@article{lvarezLarrn2016AntiplateletTV,
  title={Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation.},
  author={Alberto {\'A}lvarez-Larr{\'a}n and Arturo Pereira and Paola Guglielmelli and Juan Carlos Hern{\'a}ndez-Boluda and Eduardo Arellano-Rodrigo and Francisca Ferrer-Marin and Alimam Samah and Martin Griesshammer and Ana Kerguelen and Bjorn Andreasson and Carmen Burgaleta and J. S. Paul Schwarz and Valent{\'i}n Garc{\'i}a-Guti{\'e}rrez and Rosa Mary de Ayala and Pere Barba and Mar{\'i}a Teresa G{\'o}mez-Casares and Chiara Paoli and Beatrice Drexler and Sonja Zweegman and Mary Frances McMullin and Jan Samuelsson and Claire N Harrison and Francisco Cervantes and Alessandro Maria Vannucchi and Carlos Besses},
  journal={Haematologica},
  year={2016},
  volume={101 8},
  pages={
          926-31
        }
}
The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up of 2215 person-years free from cytoreduction, 25 thrombotic and 17 bleeding episodes were recorded. In… CONTINUE READING

Tables and Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

How I treat essential thrombocythemia.

VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Essential thrombocythemia: Biology, clinical features, thrombotic risk, therapeutic options and outcome

V. Accurso, Marco Santoro, +8 authors Sergio Siragusa
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

Thrombosis and Hemostasis in Cancer

  • Cancer Treatment and Research
  • 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin

PJ van Genderen, PG Mulder, M Waleboer, D van de Moesdijk, JJ. Michiels
  • Br J Haematol
  • 1997
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

CALR mutations are associated with lower platelet and endothelial activation than the JAK2 mutation in essential thrombocythemia

E Arellano-Rodrigo, A Alvarez-Larran, +3 authors F. Cervantes
  • J Thromb Haemost. 2015;13 (Suppl
  • 2015
VIEW 1 EXCERPT

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis

Francesca Palandri, Roberto Latagliata, +15 authors Nicola Vianelli
  • Leukemia
  • 2014